MA35036B1 - Composés bis(fluoroalkyl)-1,4-benzodiazépinone - Google Patents

Composés bis(fluoroalkyl)-1,4-benzodiazépinone

Info

Publication number
MA35036B1
MA35036B1 MA36323A MA36323A MA35036B1 MA 35036 B1 MA35036 B1 MA 35036B1 MA 36323 A MA36323 A MA 36323A MA 36323 A MA36323 A MA 36323A MA 35036 B1 MA35036 B1 MA 35036B1
Authority
MA
Morocco
Prior art keywords
compounds
benzodiazepinone
fluoroalkyl
ch2ch2cf3
ch2cf3
Prior art date
Application number
MA36323A
Other languages
English (en)
Inventor
Claude Quesnelle
Soong-Hoon Kim
Francis Lee
Ashvinikumar Gavai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35036(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA35036B1 publication Critical patent/MA35036B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) OU LEURS PROMÉDICAMENTS ; DANS LAQUELLE R1 REPRÉSENTE CH2CF3 OU CH2CH2CF3 ; R2 REPRÉSENTE CH2CF3, CH2CH2CF3, OU CH2CH2CH2CF3 ; R3 REPRÉSENTE H OU CH3; CHAQUE RA REPRÉSENTE INDÉPENDAMMENT F, CL, -CN, -OCH3 ET/OU NHCH2CH2OCH3 ; ET Z VAUT ZÉRO, 1 OU 2. ELLE CONCERNE ÉGALEMENT DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS POUR INHIBER LE RÉCEPTEUR NOTCH, ET DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES COMPOSÉS. CES COMPOSÉS SONT UTILES DANS LE TRAITEMENT, LA PRÉVENTION OU LE RALENTISSEMENT DE L'ÉVOLUTION DE MALADIES OU DE TROUBLES DANS DIVERS DOMAINES THÉRAPEUTIQUES, COMME LE TRAITEMENT DU CANCER.
MA36323A 2011-03-22 2012-03-22 Composés bis(fluoroalkyl)-1,4-benzodiazépinone MA35036B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466238P 2011-03-22 2011-03-22
PCT/US2012/030021 WO2012129353A1 (fr) 2011-03-22 2012-03-22 Composés bis(fluoroalkyl)-1,4-benzodiazépinone

Publications (1)

Publication Number Publication Date
MA35036B1 true MA35036B1 (fr) 2014-04-03

Family

ID=45894701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36323A MA35036B1 (fr) 2011-03-22 2012-03-22 Composés bis(fluoroalkyl)-1,4-benzodiazépinone

Country Status (32)

Country Link
US (2) US8629136B2 (fr)
EP (1) EP2688873B1 (fr)
JP (1) JP5873923B2 (fr)
KR (1) KR101948347B1 (fr)
CN (1) CN103717576B (fr)
AR (2) AR085471A1 (fr)
AU (1) AU2012230904B2 (fr)
BR (1) BR112013024059B1 (fr)
CA (1) CA2830902C (fr)
CL (1) CL2013002690A1 (fr)
CO (1) CO6771446A2 (fr)
CY (1) CY1116423T1 (fr)
DK (1) DK2688873T3 (fr)
EA (1) EA022530B1 (fr)
ES (1) ES2534080T3 (fr)
HR (1) HRP20150273T1 (fr)
IL (1) IL228534A (fr)
MA (1) MA35036B1 (fr)
MX (1) MX2013010420A (fr)
MY (1) MY161233A (fr)
PE (1) PE20140626A1 (fr)
PH (1) PH12013501738B1 (fr)
PL (1) PL2688873T3 (fr)
PT (1) PT2688873E (fr)
RS (1) RS53843B1 (fr)
SG (1) SG193555A1 (fr)
SI (1) SI2688873T1 (fr)
SM (1) SMT201500091B (fr)
TN (1) TN2013000372A1 (fr)
TW (1) TWI530489B (fr)
UY (1) UY33961A (fr)
WO (1) WO2012129353A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
WO2014047392A1 (fr) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés fluoroalkyl-1,4-benzodiazépinones
EP2897942B1 (fr) * 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
WO2014047370A1 (fr) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés fluoroalkyl benzodiazépinones
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
JP2015531792A (ja) * 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
EP2981267A1 (fr) * 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Traitement combiné pour le traitement de maladies prolifératives
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
CN107074788B (zh) * 2014-10-31 2019-09-20 厦门大学 取代杂环衍生物、其制备方法和用途
CN104356082B (zh) * 2014-10-31 2016-07-13 厦门大学 一类取代杂环衍生物及其制备方法
ES2808153T3 (es) * 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
CN104352488B (zh) * 2014-10-31 2016-08-31 厦门大学 一类取代杂环衍生物在制备治疗疼痛药物中的应用
CN104892532B (zh) * 2015-05-20 2017-09-08 成都理工大学 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺
DK3324977T3 (da) 2015-07-22 2022-10-17 Enanta Pharm Inc Benzodiazepinderivater som rsv-inhibitorer
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
EP3402799B1 (fr) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Composés hétérocycliques utilisés comme inhibiteurs du vrs
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
WO2018226801A1 (fr) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Dérivés d'aryldiazépine utilisés en tant qu'inhibiteurs du vrs
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (fr) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs du vrs
EP3438128B1 (fr) * 2017-08-04 2020-05-20 Alzheimur 2012 S.L. Anticorps anti preseniline pour une utilisation dans la prévention et/ou le traitement du cancer
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
CA3080138A1 (fr) * 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Procede pour la resolution de derives benzodiazepin-2-one et benzoazepin-2-one
WO2019199908A1 (fr) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Composés hétérocycliques en tant qu'inhibiteurs de vrs
WO2019215585A1 (fr) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Compositions comprenant des inhibiteurs de cd20 et des composés de bisfluoroalkyl-1,4-benzodiazépinone et leurs procédés d'utilisation
KR20210005714A (ko) 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
SG11202011327UA (en) * 2018-05-15 2020-12-30 Ayala Pharmaceuticals Inc Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
CN112236147A (zh) * 2018-05-15 2021-01-15 百时美施贵宝公司 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法
EP3801551A4 (fr) * 2018-05-24 2022-04-06 Ayala Pharmaceuticals Inc. Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
WO2020210246A1 (fr) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Composés hétérocycliques utilisés comme inhibiteurs du vrs
EP3969001A4 (fr) * 2019-05-15 2023-02-22 Ayala Pharmaceuticals Inc. Composés de bisfluoroalkyl-1,4-benzodiazépinone pour le traitement du cancer du sein activé par notch
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (fr) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dérivés de dihydroquinoxaline et de dihydropyridopyrazine utilisés comme inhibiteurs de rsv
US12577214B2 (en) 2020-09-03 2026-03-17 Bristol-Myers Squibb Company Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepinone compounds and uses thereof
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
WO2022122667A1 (fr) 2020-12-07 2022-06-16 Cellestia Biotech Ag Combinaisons pharmaceutiques pour le traitement du cancer
WO2022182861A1 (fr) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Composés hétérocycliques antiviraux
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
EP4429661A1 (fr) 2021-11-08 2024-09-18 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
EP4223292A1 (fr) 2022-02-07 2023-08-09 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (fr) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Composés antiviraux
CN120882691A (zh) * 2022-12-28 2025-10-31 伊米若梅有限公司 用于制备双(氟烷基)苯并二氮杂䓬酮化合物的中间体盐

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2555997A (en) * 1996-04-03 1997-10-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU1618000A (en) 1998-11-12 2000-05-29 Du Pont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2000038618A2 (fr) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (fr) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO SULFONAMIDES DE LACTAME UTILISES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
EP1248869A2 (fr) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
CA2395862A1 (fr) 2000-02-17 2001-08-23 Hong Liu Carbocycles et heterocycles succinoylamino utilises en tant qu'inhibiteurs de la production de la proteine a.beta.
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
AU2001251147A1 (en) 2000-03-31 2001-10-15 Dupont Pharmaceuticals Company Succinoylamino heterocycles as inhibitors of abeta protein production
CN1436175A (zh) 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ－蛋白生产抑制剂的环状内酰胺
EP1268434A1 (fr) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Lactames cycliques utiles en tant qu'inhibiteurs de la production de proteine a-beta
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
WO2001077086A1 (fr) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company LACTAMES SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINE A$g(b)
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
NZ538870A (en) 2002-09-20 2007-04-27 Arrow Therapeutics Ltd Benzodiazepine derivatives and pharmaceutical compositions containing them
EP1592684B1 (fr) 2003-02-04 2008-07-30 F. Hoffmann-La Roche Ag Derives de malonamide utilises comme inhibiteurs de la gamma-secretase
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
KR100838852B1 (ko) 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
EP1795198A1 (fr) 2005-12-09 2007-06-13 Hubrecht Laboratorium Traitement de l'esophage de Barret
CA2644136A1 (fr) 2006-02-27 2007-09-07 The Johns Hopkins University Traitement anticancereux utilisant des inhibiteurs de gamma-secretases
ES2398531T3 (es) 2006-03-27 2013-03-20 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma secretasa
AU2007299129A1 (en) 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
JP5385904B2 (ja) 2007-08-14 2014-01-08 イーライ リリー アンド カンパニー γ−セクレターゼ阻害剤
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
WO2011060051A1 (fr) 2009-11-12 2011-05-19 University Of Massachusetts Méthodes de traitement du glioblastome
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor

Also Published As

Publication number Publication date
SMT201500091B (it) 2015-05-05
EP2688873B1 (fr) 2015-01-21
US20140100365A1 (en) 2014-04-10
RS53843B1 (sr) 2015-08-31
MX2013010420A (es) 2013-10-01
CA2830902A1 (fr) 2012-09-27
JP2014511840A (ja) 2014-05-19
ES2534080T3 (es) 2015-04-17
CY1116423T1 (el) 2017-02-08
PT2688873E (pt) 2015-04-14
CN103717576A (zh) 2014-04-09
PL2688873T3 (pl) 2015-06-30
AR129859A2 (es) 2024-10-02
BR112013024059A2 (pt) 2016-12-06
CO6771446A2 (es) 2013-10-15
BR112013024059B1 (pt) 2022-01-25
SG193555A1 (en) 2013-11-29
DK2688873T3 (en) 2015-04-27
MY161233A (en) 2017-04-14
PE20140626A1 (es) 2014-05-30
HK1189218A1 (en) 2014-05-30
PH12013501738A1 (en) 2013-10-07
CA2830902C (fr) 2019-10-29
PH12013501738B1 (en) 2019-03-13
US8629136B2 (en) 2014-01-14
EA022530B1 (ru) 2016-01-29
US8822454B2 (en) 2014-09-02
TN2013000372A1 (en) 2015-01-20
IL228534A (en) 2017-02-28
IL228534A0 (en) 2013-12-31
TW201309656A (zh) 2013-03-01
CL2013002690A1 (es) 2014-02-14
KR101948347B1 (ko) 2019-02-14
JP5873923B2 (ja) 2016-03-01
CN103717576B (zh) 2015-11-25
WO2012129353A1 (fr) 2012-09-27
HRP20150273T1 (hr) 2015-06-19
NZ616876A (en) 2014-08-29
EA201391324A1 (ru) 2014-03-31
SI2688873T1 (sl) 2015-04-30
AU2012230904B2 (en) 2016-03-31
TWI530489B (zh) 2016-04-21
UY33961A (es) 2012-09-28
AU2012230904A1 (en) 2013-11-07
EP2688873A1 (fr) 2014-01-29
AR085471A1 (es) 2013-10-02
KR20140027956A (ko) 2014-03-07
US20120245151A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
MA37929A1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA34474B1 (fr) Agonistes de gpr40
MA35716B1 (fr) Formulations pharmaceutiques
MA37831B1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k
MA37990B1 (fr) Benzamides
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA40149A1 (fr) Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA30267B1 (fr) Derives amides en tant que ligands de canal ionique et compositions pharmaceutiques et procedes d'utilisation de tels derives
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
MA38206B1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées